CSL Ltd. invested $117 million to acquire an exclusive option to purchase VarmX BV, a developer of VMX-C001, a Phase 3-ready drug targeting blood coagulation reversal in patients on Factor Xa inhibitors. The option deal includes up to $2.1 billion in potential payments depending on clinical and commercial milestones. CSL plans to accelerate development and file for regulatory approval upon successful Phase 3 data.